Previous 10 | Next 10 |
Oregon and DC lead the way with decriminalization. New Jersey and California may follow in Oregon's footsteps. 2021 will be a major year for Psychedelics. For further details see: Tripping Over Future Psychedelic Catalysts
Biotechvalley Insights is initiating coverage of COMPASS Pathway (CMPS) with a "Bearish" rating at a 13 PT. CMPS has filed an IPO with an initial valuation of US$544M; since then the stock has rallied 210% as of today. I think the current share price is extremely frothy. The compa...
It’s been another week of downward momentum for the gold price. Although the yellow metal started the period fairly strong at just below the US$1,900 per ounce mark, it was trading at around US$1,870 at the time of this writing. The precious metal ‘s fa...
Psychedelic treatments, such as psilocybin could significantly alter the way modern medicine addresses mental health. “I think that psychedelic medicines offer a new paradigm in mental health,” MindMed’s co-founder and co-CEO JR Rahn told Yahoo Finance. “Traditio...
Compass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of trading, it opened at $23.40 and closed the day at $29. The stock has been trading this week in the neighborhood of $36. The Br...
FinancialBuzz.com News Commentary New York, NY (11/17/2020) – Psychedelic medicine is emerging as a breakthrough for mental health. After decades of research, drugs like psilocybin and ketamine are finally ready to move from the lab into the pharmacy and the therapist...
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q3 2020 Earnings Call Nov 12, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q3 2020 Earnings Call Transcript
Psychedelic company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the third quarter of 2020 and gave an update on recent progress across its business. The company reported a net loss of $16.6 million and essentially no income as the company is focused ...
By large, traditional drug developers have failed miserably in delivering safe and effective therapies for mental health conditions. To fill this massive void, scientists are exploring alternative options, including psychedelics, and investors are starting to lend their support, looking to ...
COMPASS Pathways ADS (CMPS): Q3 GAAP EPS of -$1.30.Cash and equivalents of $196.5M expected to fund operations into 2023.Press Release For further details see: COMPASS Pathways ADS reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...